Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Sanofi Pasteur, the vaccines division of Sanofi, is seeking partners with a common drive for excellence who will share the company’s pursuit of innovation.
Regenerative medicine company International Stem Cell Corporation (ISCO) leads the way in developing new treatments for Parkinson’s disease and other clinical conditions using a unique stem cell approach.
HitGen’s advanced encoded library technology, including its recently released nonexclusive-use OpenDEL and macrocycle libraries, affords exciting opportunities for those involved in early-stage drug discovery around challenging targets.
CHLA is engaging with internal and external partners to develop healthcare solutions that deliver lifelong benefits for conditions that originate in childhood.
Point of care testing (POCT) enables rapid diagnostic tests to be performed while a patient is at a PoC facility, without the need for complex equipment or a wait of hours to days for reports from outside labs.
The Universidad Nacional Autónoma de México’s technology transfer office—Coordinación de Innovación y Desarrollo—provides a one-stop shop for innovation emerging from Mexico.
Since 2006, BioWin, the health cluster of the Belgian region of Wallonia, has powered a renaissance of technological and scientific excellence in cell therapy and regenerative medicine.
Benitec Biopharma’s DNA-directed RNA interference platform can generate single-application therapies to silence defective genes in a wide range of diseases whilst overcoming many of the limitations of short interfering RNA.
Vaccinex’s proprietary full-length human antibody discovery engine, ActivMAb, integrates selection and manufacturing in the same mammalian host to streamline development.
The French Institute of Health and Medical Research (Inserm) has developed a unique model for technology transfer through Inserm Transfert, its subsidiary in charge of de-risking innovative preclinical projects and bridging discovery and clinical research.
Histide’s Cell Recoding Molecules provide a diverse source of nonmutagenic extracellular therapeutic agents for tissue regeneration and disease healing.
Probiodrug’s novel approach targets a modified form of β-amyloid, which has a key role in the creation of toxic Aβ oligomers. The company’s lead product is a first-in-class oral small-molecule glutaminyl cyclase inhibitor.